{name}
{subtitle}
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
city
~4 mi. (Basel, Switzerland, +130 more cities)
facility
Universitaetsspital Basel ( Site 1201)
drug
BCG solution, +1 more drug
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
city
~4 mi. (Basel, Switzerland, +199 more cities)
facility
Universitaetsspital Basel ( Site 0709)
A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)
city
~4 mi. (Basel, Switzerland, +127 more cities)
facility
Universitätsspital Basel /ID# 215892
drug
azacitidine, +2 more drugs
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
city
~48 mi. (Freiburg, Germany, +226 more cities)
facility
Universitaetsklinikum Freiburg - Medizinische Klinik ( Site 0304)
drug
enzalutamide, +1 more drug
drug type
hormone therapy, +1 more type
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
city
~48 mi. (Freiburg, Germany, +140 more cities)
facility
Universitaetsklinikum Freiburg ( Site 0199)
drug
lenvatinib, +2 more drugs
drug type
chemotherapy, +2 more types
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
city
~48 mi. (Freiburg, Germany, +93 more cities)
facility
Universitaetsklinikum Freiburg ( Site 0512)
condition
Bladder Carcinoma, +1 more condition
drug
cisplatin, +4 more drugs
drug type
chemotherapy, +3 more types